Embecta: Insulin Delivery System

2024: Product Release

On September 3, 2024, Embecta introduced a one-time insulin delivery system for adult patients with type 1 and type 2 diabetes. The article is made in the form of a patch adhering to the skin.

The system consists of a tubeless patch pump with a reservoir of 300 units of insulin. Research supported by Embecta has shown that this capacity is able to meet the needs of 64% adult patients with type 2 diabetes when worn for three days. For comparison, in the case of a 200-unit tank, the figure is only 38%.

Freepik

The pump provides adjustable delivery of the drug within three days - depending on the needs of the user. Basal and bolus insulin may be used. The first is required to maintain the necessary blood glucose levels outside meals for 24 hours: it serves to block glucose production by the liver and to prevent fat decay and ketone formation. In turn, bolus insulin (rapid action) is injected, for example, at a meal or for correction.

In addition to the patch pump, the Embecta system includes a dedicated controller with Bluetooth wireless support and a color touch screen. It allows you to adjust the insulin delivery process, as well as view related information. The Embecta system has received approval from the U.S. Food and Drug Administration (FDA).

Our team focused on developing a patch pump that is able to remove some of the most significant barriers when using similar therapy in people with diabetes. This platform also serves as the basis for an automated insulin delivery system in development, Embecta states.[1]

Notes